

Cite this: *Chem. Sci.*, 2019, 10, 9872

All publication charges for this article have been paid for by the Royal Society of Chemistry

Ureidopeptide GLP-1 analogues with prolonged activity *in vivo* via signal bias and altered receptor trafficking†

Juliette Fremaux,^a Claire Venin,^a Laura Mauran,^a Robert Zimmer,^a Florian Koensgen,^c Didier Rognan,^c Stavroula Bitsi,^d Maria A. Lucey,^e Ben Jones,^e Alejandra Tomas,^d Gilles Guichard^b and Sébastien R. Goudreau^{b*}

The high demand of the pharmaceutical industry for new modalities to address the diversification of biological targets with large surfaces of interaction led us to investigate the replacement of α -amino acid residues with ureido units at selected positions in peptides to improve potency and generate effective incretin mimics. Based on molecular dynamics simulations, N-terminally modified GLP-1 analogues with a ureido residue replacement at position 2 were synthesized and showed preservation of agonist activity while exhibiting a substantial increase in stability. This enabling platform was applied to exenatide and lixisenatide analogues to generate two new ureidopeptides with antidiabetic properties and longer duration of action. Further analyses demonstrated that the improvement was due mainly to differences in signal bias and trafficking of the GLP-1 receptor. This study demonstrates the efficacy of single α -amino acid substitution with ureido residues to design long lasting peptides.

Received 26th April 2019
Accepted 27th August 2019

DOI: 10.1039/c9sc02079a

rsc.li/chemical-science

Introduction

Backbone modifications are a powerful strategy to improve peptide properties as they generally ameliorate their protection against proteolysis and therefore their duration of action.^{1,2} Such an approach is far from trivial as modifying the backbone of peptides has generally drastic negative impacts on binding properties, and consequently, potency. Noteworthy aza-amino acids^{3,4} and β -amino acids⁵⁻⁷ have proved to be efficient α -amino acid substitutions. Despite the potential of these approaches, new enabling platforms based on backbone modifications are still needed to meet the increasingly demanding requirements of the pharmaceutical industry in peptide mimicry.⁸

In the past decade, the incretin glucagon-like peptide-1 (GLP-1) has been largely studied because of its blood glucose control properties which have led to multiple new treatments for type 2 diabetes mellitus (T2DM).⁹ This pharmacological

target remains of considerable ongoing interest as several studies indicate that GLP-1 analogues could be used for other important indications such as obesity, major adverse cardiac events, Alzheimer's disease, or non-alcoholic steatohepatitis (NASH).⁹ One particular problem with the use of native GLP-1, a 29 amino acid natural peptide hormone, is its short *in vivo* half-life of 2–3 min.¹⁰ Many modifications have therefore been developed to prolong the GLP-1 lasting period, notably, sequence remodelling and extension (exenatide and lixisenatide),¹¹ fatty acid acylation to promote binding to plasma albumin (liraglutide and semaglutide),¹¹ bonding or fusion to large proteins (dulaglutide, albiglutide, and efpeglenatide),¹¹ non-natural amino acid replacements,¹² side chain cross linking,¹³ and more recently $\alpha \rightarrow \beta$ -residue replacements,¹⁴ thioamide,¹⁵ and peptide-oligourea hybrids¹⁶ (Fig. 1). A common modification of GLP-1 analogues is the replacement of Ala2 with another amino acid (*i.e.* Gly) to prevent proteolytic cleavage by DPP-4.^{10,11} However, despite having a glycine in position 2, exenatide, an FDA approved once-weekly treatment for T2DM, is still susceptible to degradation at its N-terminus.¹⁷ We therefore hypothesize that modifying the backbone of exenatide might improve its proteolytic stability and prolong its activity *in vivo*. However, backbone modifications at the N-terminal part of incretins and other ligands of class B GPCRs have scarcely been reported^{15,18-20} which reflects the difficulty to mimic the complex network of interactions in the binding pocket of the receptor transmembrane domain.²¹

^aUREKA – ImmPharma Group, 2 rue Robert Escarpit, 33607 Pessac, France. E-mail: sebastien.goudreau@immupharma.com

^bUniv. Bordeaux, CNRS, CBMN, UMR 5248, Institut Européen de Chimie et Biologie, 2 rue Robert Escarpit, 33607 Pessac, France. E-mail: g.guichard@tecb.u-bordeaux.fr

^cLaboratoire d'Innovation Thérapeutique, UMR7200 CNRS-Université de Strasbourg, 74 route du Rhin, 67400 Illkirch, France

^dSection of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK

^eSection of Investigative Medicine, Imperial College London, London W12 0NN, UK

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02079a






Fig. 1 Schematic representation of different GLP-1 analogues previously reported and the present approach (ureidopeptide). GLP-1 analogue modifications are highlighted in colour; orange: β -amino acids, purple: macrocycles, blue and yellow: lipidation, green: ureido residue.

Herein we report the utilization of a ureido residue replacement at position 2 of GLP-1 analogues to improve their pharmacodynamic properties *via* selective enhancement of G

protein-dependent cAMP signalling and altered GLP-1R trafficking.

Results and discussion

Peptide design, synthesis and functional assays


Although oligourea foldamers^{16,22–25} have recently been reported to be effective α -helix mimics, their constitutive units – ureido residues – have scarcely been studied in the context of single α -amino acid replacements.²⁶ Therefore, the ability of GLP-1 analogues with a ureido unit (X^u) (Table 1) at position 2 (*e.g.* GLP-1[A^u]² (3)) to interact with the GLP-1 receptor (GLP-1R) was first tested *in silico* by molecular dynamics simulation (see the ESI[†]). The cryo-EM structure of GLP-1R (PDB ID: 5VA1),²¹ which contains GLP-1 as the ligand, was used both as a starting point and as a comparator to evaluate the binding mode of GLP-1[A^u]² (3).

As seen from the predicted model, the ureido peptide 3 sits deeper in the cavity of the transmembrane domain (TMD) compared to native GLP-1, and its N-terminus is engaged in new H-bond interactions with the receptor (Fig. 2). In particular, the terminal amino group of His1 and main chain NHs of the Ala^u2 unit are H-bonded to Glu364 and Glu387 located in transmembrane helices TM6 and TM7, respectively. Moreover, the salt bridge between Glu3 and Arg190 is supplemented by two new H-bonds to Tyr145 and Tyr152. On the basis of these results, we synthesized compound 3 to further investigate to

Table 1 Bioactivity in cAMP production functional assays using HEK293 cells transfected with GLP-1R and the mouse plasma half-life of GLP-1, exenatide, lixisenatide and cognate monosubstituted analogues

Sequence	Compound	EC ₅₀ (pM) ^a (IC ₅₀ (nM)) ^b	SEM (pM) ^c (SEM (nM)) ^d	Potency (%) ^e	Mouse plasma $t_{1/2}$ (h)	SEM (h) ^f
1 H H A EGTFTSDVSSYLEGQAA K E F I A W L V K G R G O H	GLP-1					
2 H H A EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1-NH ₂	3.2 ^g (2.4)	0.4 (2)	100	0.14	0.01
3 H H A ^u EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1[A^u] ²	2.7 (32)	0.3 (8)	117	0.24	0.02
4 H H V ^A EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1[γA] ²	31	3	10	0.23	0.02
5 H H A ^c EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1[A^c] ²	24	4	13	0.21	0.05
6 H H A ^u EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1[A^{u2}] ²	12	2	25	0.37	0.02
7 H H G ^u EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1[G^u] ²	5.3	0.2	59	0.22	0.02
8 H H V ^u EGTFTSDVSSYLEGQAA K E F I A W L V K G R G N H ₂	GLP-1[V^u] ²	2119	50	<0.01	0.30	0.05
9 H H G EGTFTSDLSKQMEEEAV R L F I E W L K N G G P S S G A P P P S N H ₂	Exenatide	0.89 (0.18 ^h)	0.07 (0.07 ⁱ)	355	5.4	1.2
10 H H G EGTFTSDLSKQLEEEAV R L F I E W L K N G G P S S G A P P P S N H ₂	Ex4 ^l	1.7	0.2	192	5.4	0.9
11 H H A ^u EGTFTSDLSKQLEEEAV R L F I E W L K N G G P S S G A P P P S N H ₂	Ex4 ^l [A^u] ²	4.0 (1.9)	0.2 (0.4)	79	9.3	0.3
12 H H G EGTFTSDLSKQMEEEAV R L F I E W L K N G G P S S G A P P S 6 K N H ₂	Lixisenatide	2.0	0.1	161	3.3	0.4
13 H H G EGTFTSDLSKQLEEEAV R L F I E W L K N G G P S S G A P P S 6 K N H ₂	Lixi ^l	1.3	0.1	251	3.6	0.5
14 H H A ^u EGTFTSDLSKQLEEEAV R L F I E W L K N G G P S S G A P P S 6 K N H ₂	Lixi ^l [A^u] ²	1.1	0.1	287	6.6	0.7
15 H H A EGTFTSDVSSYLEGQAA [K*] E F I A W L V R G R G O H	Liraglutide	15.0	0.4	21	26	4

^aGLP-1R potency (EC₅₀). ^bValue in parentheses: half maximal inhibitory concentration to inhibit the binding of [¹²⁵I]GLP-1 (7-36) to GLP-1R (IC₅₀). ^cSEM on the EC₅₀. ^dValue in parentheses: SEM of the IC₅₀. ^ePercentage of potency compared to GLP-1-NH₂. ^fSEM of the mouse plasma half-life. ^gCalculated from 6 replicates ($n = 6$). ^hCalculated from 2 replicates ($n = 2$). ⁱStandard error. Unless otherwise stated, the data are mean \pm SEM ($n = 3$). GLP-1R: GLP-1 receptor; EC₅₀: half maximal effective concentration; IC₅₀: half maximal inhibitory concentration; SEM: standard error of the mean.






Fig. 2 Predicted structure of the GLP-1R/GLP-1[Ala^u]² complex compared to the cryo-EM structure of the GLP-1R/GLP-1 complex. (a and b) GLP-1 (in orange) in the GLP-1R TMD and an enlarged image (b) of the N-terminal part (extracted from the cryo-EM structure of the GLP-1R/GLP-1 complex (PDB 5VA1));²¹ (c and d) predicted structure of GLP-1[Ala^u]² (3) (in blue with Ala^u2 in green) in the GLP-1R TMD and an enlarged image (d) of the N-terminal part.

what extent agonist activity is retained upon Ala → Ala^u replacement at position 2. The synthesis of GLP-1[Ala^u]² (3) was readily achieved using standard solid phase synthesis with *N*-Fmoc protected amino acids and succinimidyl-[(2*S*)-2-azidopropyl]carbamate for ureido insertion.²⁷ The agonistic activity of the oligomer was determined *in vitro* using HEK293 cells transfected with GLP-1R (Table 1) and βTC6 cells which express GLP-1R endogenously (see ESI, Table S1†) by measuring the receptor-mediated cAMP production in the presence of the agonist. The results show that 3 is active with an EC₅₀ of 2.7 pM which is equivalent to that of GLP-1-NH₂ (2) (3.2 pM). An agonist radioligand assay was then used to further evaluate the interaction of 3 with GLP-1R (Table 1). The data show that 3 binds GLP-1 in the nM range (IC₅₀ = 32 nM) but less tightly than 2 (2.4 nM). It is noteworthy that despite a 10-fold reduction in binding efficacy, the agonist activity (EC₅₀) of 3 is largely retained.

To validate our hypothesis that the additional NH of urea is involved in the binding, we synthesized two new analogues in which the urea NH in 3 was replaced by either a CH₂ group or an oxygen (O) to generate γ-amino-acid- and carbamate-containing peptides GLP-1[γA]² (4) and GLP-1[A^c]² (5). These modifications cause a 5- to 10-fold loss in potency relative to 3. Attempts to vary the nature of the side chain of the ureido unit in 3 (*e.g.* Val^u,

Ile^u, Phe^u, Glu^u, Ser^u, *etc.*) led to analogues with significantly reduced biological activity (see the ESI, Table S1†). These results are consistent with those of the previously reported SAR studies²⁸ and with the model presented in Fig. 2b which shows the limited space available in the pocket around the ureido residue to accommodate larger side chains. Exchanging the methyl side chain for an isopropyl (Val^u, 8), removing the methyl side chain (Gly^u, 7) and shifting the methyl group of the ureido residue from the β- to the α-carbon (Ala^{uα}, 6) were also tried, but again with a loss of potency (>1000-, 5- and 24-fold respectively), demonstrating that the methyl side chain on the β-carbon is optimal to stabilize GLP-1R in the fully active state.

We then investigated the scope of this approach by incorporating the Ala^u2 modification in exenatide (9) and lixisenatide (12), two GLP-1 analogues currently approved by the FDA for the treatment of T2DM. More precisely, Ala^u was introduced in the Leu14 analogues Ex4^L (10) and Lixi^L (13), which are less susceptible to oxidation and show similar potency.²⁹ As before, the resulting monosubstituted ureido analogues 11 and 14 displayed potent agonist activities, comparable to that of the native peptide in both cases. Binding studies were also performed on exenatide (9) and the ureidopeptide analogue 11 and again a ten-fold difference in binding (IC₅₀ of 0.18 and 1.9 nM, respectively) was observed, consistent with the results obtained for 3 (Table 1).

Mouse plasma and *in vivo* studies in mice

To further evaluate the potential benefits of the Ala² → Ala^u2 replacement in GLP-1R activating peptides, a comparative stability study in mouse plasma was conducted on compounds 2–14. Solutions of peptides, ureidopeptides or oligomers were treated with mouse plasma and their stabilities were assessed. Remarkably, in all cases, the introduction of the ureido residue in position 2 resulted in a substantially longer *in vitro* half-life. Ex4^L[Ala^u]² (11) was found to persist for significantly longer in the serum (half-life of 9.3 hours) than Ex4^L (10) for which a half-life of 5.4 hours was measured. So by replacing only one amino acid with a ureido alanine (Ala^u) we increased the half-life in mouse plasma by 1.7-fold with no impact on the EC₅₀. For the next step, we conducted a series of experiments in mice to see if this improvement could be translated *in vivo*. Healthy mice were fasted for 6 hours and acutely treated with 1 μg (10 nmol kg⁻¹) of GLP-1 analogues injected *i.v.* 3, 6, and 9 hours before performing an intra-peritoneal glucose tolerance test (IPGTT) (Fig. 3).

When the IPGTT is performed 3 hours after the administration of the GLP-1 analogues or the vehicle, we observe a strong control over blood glucose for both exenatide (9) and Ex4^L[Ala^u]² (11) compared to the vehicle, with a significant decrease even at T0 before the administration of glucose (Fig. 3a). Interestingly, after 6 hours, we can already observe that exenatide has partially lost its efficacy while 11 is still fully active (Fig. 3b). In the experiment shown in Fig. 3c, glucose was administered 9 hours after injection of ureidopeptides 11 and 14 which were directly compared to the lixisenatide analogue Lixi^L (13) as a reference. Lixisenatide is a once daily GLP-1R






Fig. 3 Pharmacodynamic studies in healthy mice (C57BL/6J, male, 20–25 g). Dosage: $1 \mu\text{g}$ per mouse (10 nmol kg^{-1}) i.v. Formulation: $4 \mu\text{g mL}^{-1}$ in PBS $1\times$. IPGTT: glucose 2 g kg^{-1} i.p. at T0. (a) IPGTT 3 h after dosing: trace and AUC. Fasted 6 h. (b) IPGTT 6 h after dosing: trace and AUC. Fasted 6 h. (c) IPGTT 9 h after dosing: trace and AUC. Fasted 9 h. (d) Fasted blood glucose before and after dosing and before the IPGTT 9 h in (c). Data are mean \pm SEM ($n = 6$). Statistics by two-way ANOVA and Bonferroni post-test: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, comparing the vehicle to oligomers; one way ANOVA with Dunnett's multiple comparison test: $\#p < 0.05$, $\#\#p < 0.01$, $\#\#\#p < 0.001$, comparing the vehicle to oligomers. IPGTT: intraperitoneal glucose tolerance test; AUC: area under the curve; i.v.: intra venous; i.p.: intra peritoneal.

agonist with an increased binding affinity to the receptor and a prolonged half-life *in vivo* compared to exenatide.¹¹ In this case, Lixi^L (13) shows a small glucose-lowering effect 9 hours after treatment, compared to the vehicle. In contrast, 11 and 14 demonstrated a strong ability to control blood glucose levels with almost no increase in the IPGTT curves. These results are in accordance with the fasting blood glucose curves covering the 9 hours preceding the IPGTT where we can see that the effect of the ureidopeptides 11 and 14 is maintained while in the case of 13 the blood glucose tends to increase after 4 hours (Fig. 3d). In order to quantify the improvements of the ureidopeptides *in vivo*, a dose–response relationship study was conducted to determine the ED₅₀ of 9, 11, 13 and 14 (Fig. 4). Mice were treated with different doses of analogues and IPGTTs were performed after 6 h. From these results dose–response curves were obtained and *in vivo* ED₅₀ values were calculated. Exenatide (9) and Lixi^L (13) showed ED₅₀ values of 2.4 and 2.2 nM, respectively, while the ureidopeptide analogues Ex4^L[A¹¹]² (11) and Lixi^L[A¹¹]² (14) demonstrated a five-fold improvement with ED₅₀ values of 0.48 and 0.46 nM, respectively.

These studies clearly show that introducing a ureido alanine at position 2 of a GLP-1 analogue can significantly prolong its efficacy *in vivo*.

In another study in healthy mice, liraglutide (15) and ureidopeptides 11 and 14 were administered with the same dose as in the IPGTTs and their fed blood glucose was followed over 30 hours to assess their maximum duration of action (Fig. 5a). Interestingly, all three compounds had similar fed blood glucose curves which suggested that 11 and 14 have a similar lasting period to liraglutide. Liraglutide is a long acting FDA-approved GLP-1 analogue with a fatty acid chain attached on Lys26 to increase albumin binding and is used as a once daily treatment (Table 1).¹¹ To further validate the potential relevance of ureido analogues of GLP-1 for treating T2DM, we next




Fig. 4 Dose–response relationships of exenatide (9), Lixi^L (13) and their putative ureidopeptides Ex4^L[A¹¹]² (11) and Lixi^L[A¹¹]² (14) in healthy mice (C57BL/6J, male, 25–30 g). Dose response relationships from IPGTT results shown in the ESI, Fig. S4†, 3-parameter fits of area-under-curve values ($n = 8$). Dosage and formulation: 0.01 to 10 nmol kg^{-1} in 100 μL saline i.p. Fasted 4 h prior to agonist administration. IPGTT (2 mmol kg^{-1} glucose) performed 6 hours after administration of indicated agonist dose in lean C57BL/6 mice. Data are mean \pm SEM.

conducted a study on diabetic db/db mice. The mice were treated *via* the subcutaneous route, once daily over 15 days with 11 (25 nmol kg^{-1}) or with liraglutide (25 nmol kg^{-1}). A number of parameters were measured during the experiment such as body weight, plasma insulin, fed blood glucose, and glycated haemoglobin (HbA1c) levels (Fig. 5 and the ESI†). Fed blood glucose showed similar reductions as in healthy mice, confirming the results while suggesting that 11 might be even better than liraglutide (Fig. 5b). However liraglutide tends to have a better control on the fasted blood glucose as demonstrated by the blood glucose at T0 in the IPGTT after 6 hours of administration of the GLP-1 analogues, which is reflected in a better AUC (Fig. 5c). Interestingly, treatment with 11 led to






Fig. 5 Comparative pharmacodynamics of Ex⁴L[A^U]² (**11**), Lixi^L[A^U]² (**14**) and liraglutide (**15**) in mice. (a) Fed blood glucose in healthy mice (C57BL/6J, male, 20–25 g): trace and AUC ($n = 6$). Dosage: $1 \mu\text{g}$ per mouse (10 nmol kg^{-1}) i.v. Formulation: $4 \mu\text{g mL}^{-1}$ in PBS $1\times$. (b–e) Study on db/db mice treated over 15 days ($n = 10$). Dosage: $100 \mu\text{g kg}^{-1}$ (25 nmol kg^{-1}) s.c. once a day ($n = 10$). Formulation: $20 \mu\text{g mL}^{-1}$ in PBS $1\times$. (b) Fed blood glucose before and after treatment on day 7: trace and AUC. (c) OGTT 6 hours after dosing on day 12: trace and AUC. OGTT: glucose 1 g kg^{-1} i.p. at T0. (d) Body weight across the study. (e) Plasma insulin before and after the OGTT on day 12. Data are mean \pm SEM. Statistics by two-way ANOVA and Bonferroni post-test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, comparing the vehicle to oligomers; one way ANOVA with Dunnett's multiple comparison test: # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$, comparing the vehicle to oligomers. IPGTT: intraperitoneal glucose tolerance test; AUC: area under the curve; i.v.: intra venous; s.c.: subcutaneous; i.p.: intra peritoneal.

a significant increase in insulin production compared to that with the vehicle and is superior to liraglutide (Fig. 5e).

Overall, the data obtained in this study showed that **11** and liraglutide have similar activities in the db/db mouse model. This is remarkable considering that liraglutide's longer lasting period is due to it binding to serum albumin through its lipid side chain, while it is unlikely that Ex⁴L[A^U]² **11** binds to albumin to the same extent.

Pharmacokinetic studies

In light of these interesting results, we sought to understand the underlying causes of such improvements of exenatide and lixisenatide by the substitution of one amino acid over 39 and 45, respectively. Our hypothesis was that the cleavage between positions 1 and 2 of exenatide (**9**) and lixisenatide (**12**) was a determining factor for their *in vivo* half-life¹⁷ and, as we managed to improve the proteolytic stability of the peptides *in vitro*, as demonstrated by the increased mouse plasma stability, this would be reflected in improved *in vivo* half-life profiles. To validate this hypothesis, we conducted pharmacokinetic studies on healthy mice with Ex⁴L (**10**) and Ex⁴L[A^U]² (**11**). Surprisingly, no significant difference was observed between the two analogues (ESI[†]).

GLP-1R biased signalling and trafficking

As it was difficult to explain the full extent of the pharmacodynamic effects solely from the *in vitro* plasma stability, we sought other hypotheses that would help to fully account for our *in vivo* results. It has been reported in recent studies that modifying GLP-1 and GLP-1-related peptides can lead to the selective

enhancement of particular intracellular signalling pathways, usually referred to as “signal bias”.^{14,30,31} In one example, exenatide-derived peptides with amino acid substitutions close to the N-terminus (such as “exenatide-F1”) showed reduced recruitment of β -arrestin whilst maintaining full agonist behaviour for G protein-dependent cAMP signalling;³⁰ furthermore, these compounds displayed markedly reduced tendencies to induce GLP-1R endocytosis. These properties allowed for enhancement of insulin secretion *via* a combination of reduced GLP-1R desensitisation and preservation of surface GLP-1Rs available to the extracellular agonist. We hypothesized that a similar phenomenon may apply to the ureidopeptides described herein which also contain modifications at the N-terminal portion of exenatide. Therefore, signal bias and effects on GLP-1R endocytosis were assessed for Ex⁴L (**10**), Lixi^L (**13**) and their ureidopeptide analogues **11** and **14**, respectively (Fig. 6). Interestingly, in both cases, the recruitment of β -arrestin to GLP-1Rs was selectively diminished, as shown in Fig. 6a, with quantification of bias *via* the operational model³² confirming a strong preference for cAMP signalling (Fig. 7). Moreover, endocytosis of the GLP-1R was noticeably reduced after treatment with ureido- compared to non-ureido-peptides, as assessed by confocal microscopy in INS-1 832/3 beta cells with endogenous GLP-1R knocked out by CRISPR/Cas9,³³ modified to express SNAP-tagged human GLP-1R which was surface-labelled prior to agonist treatment (Fig. 6b and the ESI, Fig. S7[†]). The reduced residence time of **11** suggested by its increased IC₅₀, in conjunction with this reduced internalisation propensity, is compatible with the previously described relationship between agonist binding kinetics and GLP-1R






Fig. 6 GLP-1R biased signalling and trafficking studies. (a) Cyclic AMP (cAMP) and β -arrestin-2 (β arr2) responses in PathHunter CHO-GLP-1R cells, 30 min stimulation, all ligands and pathways run in parallel, results normalized to global maximum responses (cAMP) or GLP-1-NH₂ (2) maximal response (β arr2), 4-parameter fit shown, $n = 5$ independent experiments. (b) Confocal analysis of SNAP-GLP-1R internalization in SNAP-GLP-1R-expressing INS-1 832/3 cells labeled with SNAP-Surface 549 probe (red) for 30 min and then stimulated with 10 nM of the indicated ligand for a further 30 min. Nuclei (DAPI), blue; size bars, 10 μ m. (c) Insulin secretion in INS-1 832/3 cells, 16 h stimulation at 11 mM glucose, all ligands run in parallel, normalised to basal response in each assay, 3-parameter fit shown, $n = 5$ independent experiments, E_{max} compared by 2-way repeat measures ANOVA with Tukey's test.




Fig. 7 GLP-1R biased signalling. Signal bias calculated from the data shown in Fig. 6a, expressed relative to GLP-1-NH₂ (2), determined using a modified form of the operational model (see Methods for details[†]), and 1-way randomised block ANOVA with Tukey's test of difference between Log R values for cAMP vs. β -arrestin-2 responses for each ligand.

endocytosis.³⁰ In keeping with the cellular mechanism described by Jones *et al.*,³⁰ both exenatide and lixisenatide ureidopeptide analogues **11** and **14** showed significantly increased insulin release (Fig. 6c) assessed *in vitro*, mirroring our previous observations in the db/db mouse study (Fig. 5e). The combination of reduced β -arrestin recruitment and GLP-1R endocytosis, associated with enhanced insulin release *in vitro* and *in vivo*, is remarkably consistent with the characteristics of exenatide-F1,³⁰ suggesting a similar mechanism of action. Moreover, we note similarities with another biased GLP-1R agonist, exendin-P5,³¹ which shows selectively increased coupling to cAMP signalling in spite of somewhat reduced binding affinity *versus* exenatide.³⁴ Further investigations are required to fully understand the mechanism of action of these analogues and will be reported in due course.

Conclusions

In summary, we rationalized the design of singly substituted ureido analogues of GLP-1 using molecular modelling, showing that the replacement of the amino acid in position 2 of GLP-1 with an ureido alanine (Ala^U) does not impair its agonist activity. Moreover, the same modification introduced in exenatide and lixisenatide considerably prolongs their efficacy *in vivo* with a significant reduction of blood glucose levels observed over at least 9 hours in healthy mice. Additionally, we have shown that this monosubstituted analogue is also active in db/db mice, a type 2 diabetes mellitus animal model, giving similar result to the FDA approved liraglutide. A key mechanism for the improved biological efficacy of these compounds appears to be the enhancement of insulin secretion *via* effects on signal bias and GLP-1R trafficking on pancreatic β -cells. Indeed, introducing a ureido residue at position 2 of exenatide and lixisenatide preserves their efficacy while diminishing their affinity, which may result in a shorter residence time in the receptor and therefore reduced endocytosis of the GLP-1 receptor. Further studies are required to fully elucidate this mechanism.

All in all, this study demonstrates and validates the approach of substituting simple α -amino acids with their ureido counterparts to improve the pharmacological properties of biologically relevant peptides. The evaluation of replacing multiple amino acids to generate ureidopeptides with multiple isolated ureido residues and/or the combination of this approach with other strategies like acylation with fatty acids or combination with oligoureas to generate ureidopeptide-oligourea hybrids will be reported in due course.



Author contributions

J. F., C. V., R. H. Z., G. G. and S. R. G. designed the analogues. J. F. and C. V. synthesized the analogues. L. M. performed the mouse plasma degradation assays and the functional assays on the HEK293 cells. F. K. and D. R. performed the molecular dynamics simulations. M. A. L. and B. J. performed the dose-response study. S. B., B. J. and A. T. performed the biased signalling and trafficking studies. G. G. and S. R. G. conceived the project. S. R. G. supervised the project. J. F., G. G. and S. R. G. analyzed the data and wrote the manuscript.

Conflicts of interest

The authors declare the following competing financial interests. J. F., C. V., L. M., R. H. Z., G. G., and S. R. G. are inventors on a patent application covering the GLP-1 analogues described here. J. F., C. V., L. M., R. H. Z. and S. R. G. work for UREKA Sarl, which is pursuing biomedical applications of ureidopeptides.

Acknowledgements

This work was supported by UREKA Sarl, Immupharma Group. Support from the Conseil Regional de Nouvelle Aquitaine (Project #14004308), CNRS, Univ. Bordeaux and ANR (Grant ANR-15-CE07-0010) is also gratefully acknowledged. This work has benefited from the facilities and expertise of the IECB Biophysical and Structural Chemistry platform (BPCS), CNRS UMS3033, Inserm US001, Univ. Bordeaux, and PCBIS – Tech-MedILL, CNRS UMS 3286 Univ. Strasbourg. We thank the Calculation Center of the CNRS-IN2P3 (Villurbanne, France) for allocation of computing time and excellent support. S. Bitsi, B. Jones and A. Tomas are supported by an MRC Project Grant (MR/R010676/1); B. Jones is additionally supported by an NIHR Clinical Lectureship. All animal protocols followed by Physiogenex S. A. S. were reviewed and approved by the local (Comité régional d'éthique de Midi-Pyrénées) and national (Ministère de l'Enseignement Supérieur et de la Recherche) ethics committees (protocol number 05049-06). For the dose-response study, animal procedures were approved by the British Home Office under the UK Animal (Scientific Procedures) Act 1986 (Project Licence 70/7596). All animal protocols followed by the Tech-MedILL service were reviewed and approved by the agriculture ministry regulating animal research in France (Ethics Regional Committee for Animal Experimentation Strasbourg, APAFIS 1341#2015080309399690).

Notes and references

- 1 M. Erak, K. Bellmann-Sickert, S. Els-Heindl and A. G. Beck-Sickinger, *Bioorg. Med. Chem.*, 2018, **26**, 2759–2765.
- 2 E. Valeur, S. M. Guéret, H. Adihou, R. Gopalakrishnan, M. Lemurell, H. Waldmann, T. N. Grossmann and A. T. Plowright, *Angew. Chem., Int. Ed.*, 2017, **56**, 10294–10323.
- 3 R. Chingle, C. Proulx and W. D. Lubell, *Acc. Chem. Res.*, 2017, **50**, 1541–1556.

- 4 Y. Zhang, R. M. Malamakal and D. M. Chenoweth, *J. Am. Chem. Soc.*, 2015, **137**, 12422–12425.
- 5 L. M. Johnson and S. H. Gellman, in *Methods in Enzymology*, Elsevier, 2013, vol. 523, pp. 407–429.
- 6 D. Seebach, E. Dubost, R. I. Mathad, B. Jaun, M. Limbach, M. Löweneck, O. Flögel, J. Gardiner, S. Capone, A. K. Beck, H. Widmer, D. Langenegger, D. Monna and D. Hoyer, *Helv. Chim. Acta*, 2008, **91**, 1736–1786.
- 7 N. Koglin, C. Zorn, R. Beumer, C. Cabrele, C. Bubert, N. Sewald, O. Reiser and A. G. Beck-Sickinger, *Angew. Chem., Int. Ed.*, 2003, **4**.
- 8 S. Mimmi, D. Maisano, I. Quinto and E. Iaccino, *Trends Pharmacol. Sci.*, 2019, **40**, 87–91.
- 9 D. J. Drucker, *Cell Metab.*, 2018, **27**, 740–756.
- 10 L. Jessen, B. A. Aulinger, J. L. Hassel, K. J. Roy, E. P. Smith, T. M. Greer, S. C. Woods, R. J. Seeley and D. A. D'Alessio, *Endocrinology*, 2012, **153**, 5735–5745.
- 11 J. Y. Cheang and P. M. Moyle, *ChemMedChem*, 2018, **13**, 662–671.
- 12 H. Meng, S. T. Krishnaji, M. Beinborn and K. Kumar, *J. Med. Chem.*, 2008, **51**, 7303–7307.
- 13 E. N. Murage, G. Gao, A. Bisello and J.-M. Ahn, *J. Med. Chem.*, 2010, **53**, 6412–6420.
- 14 M. V. Hager, L. M. Johnson, D. Wootten, P. M. Sexton and S. H. Gellman, *J. Am. Chem. Soc.*, 2016, **138**, 14970–14979.
- 15 X. Chen, E. G. Mietlicki-Baase, T. M. Barrett, L. E. McGrath, K. Koch-Laskowski, J. J. Ferrie, M. R. Hayes and E. J. Petersson, *J. Am. Chem. Soc.*, 2017, **139**, 16688–16695.
- 16 J. Fremaux, C. Venin, L. Mauran, R. H. Zimmer, G. Guichard and S. R. Goudreau, *Nat. Commun.*, 2019, **10**, 924.
- 17 S. Liao, Y. Liang, Z. Zhang, J. Li, J. Wang, X. Wang, G. Dou, Z. Zhang and K. Liu, *PLoS One*, 2015, **10**, e0116805.
- 18 X. Bai, Y. Niu, J. Zhu, A.-Q. Yang, Y.-F. Wu and X.-S. Ye, *Bioorg. Med. Chem.*, 2016, **24**, 1163–1170.
- 19 S. Liu, R. W. Cheloha, T. Watanabe, T. J. Gardella and S. H. Gellman, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, 201815294.
- 20 R. W. Cheloha, B. Chen, N. N. Kumar, T. Watanabe, R. G. Thorne, L. Li, T. J. Gardella and S. H. Gellman, *J. Med. Chem.*, 2017, **60**, 8816–8833.
- 21 Y. Zhang, B. Sun, D. Feng, H. Hu, M. Chu, Q. Qu, J. T. Tarrasch, S. Li, T. Sun Kobilka, B. K. Kobilka and G. Skiniotis, *Nature*, 2017, **546**, 248–253.
- 22 E. Teyssières, J.-P. Corre, S. Antunes, C. Rougeot, C. Dugave, G. Jouvion, P. Claudon, G. Mikaty, C. Douat, P. L. Goossens and G. Guichard, *J. Med. Chem.*, 2016, **59**, 8221–8232.
- 23 M. Pasco, C. Dolain and G. Guichard, in *Comprehensive Supramolecular Chemistry II*, Elsevier, 2017, pp. 89–125.
- 24 J. W. Checco and S. H. Gellman, *Curr. Opin. Struct. Biol.*, 2016, **39**, 96–105.
- 25 J. Fremaux, L. Mauran, K. Pulka-Ziach, B. Kauffmann, B. Odaert and G. Guichard, *Angew. Chem.*, 2015, **127**, 9954–9958.
- 26 K. Burgess, H. Shin and D. S. Linthicum, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 907–909.
- 27 C. Douat-Casassus, K. Pulka, P. Claudon and G. Guichard, *Org. Lett.*, 2012, **14**, 3130–3133.



- 28 C. de Graaf, D. Donnelly, D. Wootten, J. Lau, P. M. Sexton, L. J. Miller, J.-M. Ahn, J. Liao, M. M. Fletcher, D. Yang, A. J. H. Brown, C. Zhou, J. Deng and M.-W. Wang, *Pharmacol. Rev.*, 2016, **68**, 954–1013.
- 29 D. M. Hargrove, E. S. Kendall, J. M. Reynolds, A. N. Lwin, J. P. Herich, P. A. Smith, B. R. Gedulin, S. D. Flanagan, C. M. Jodka, J. A. Hoyt, K. M. McCowen, D. G. Parkes and C. M. Anderson, *Regul. Pept.*, 2007, **141**, 113–119.
- 30 B. Jones, T. Buenaventura, N. Kanda, P. Chabosseau, B. M. Owen, R. Scott, R. Goldin, N. Angkathunyakul, I. R. Corrêa Jr, D. Bosco, P. R. Johnson, L. Piemonti, P. Marchetti, A. M. J. Shapiro, B. J. Cochran, A. C. Hanyaloglu, A. Inoue, T. Tan, G. A. Rutter, A. Tomas and S. R. Bloom, *Nat. Commun.*, 2018, **9**, 1602.
- 31 H. Zhang, E. Sturchler, J. Zhu, A. Nieto, P. A. Cistrone, J. Xie, L. He, K. Yea, T. Jones, R. Turn, P. S. Di Stefano, P. R. Griffin, P. E. Dawson, P. H. McDonald and R. A. Lerner, *Nat. Commun.*, 2015, **6**, 8918.
- 32 T. Kenakin, C. Watson, V. Muniz-Medina, A. Christopoulos and S. Novick, *ACS Chem. Neurosci.*, 2012, **3**, 193–203.
- 33 J. Naylor, A. T. Suckow, A. Seth, D. J. Baker, I. Sermadiras, P. Ravn, R. Howes, J. Li, M. R. Snaith, M. P. Coghlan and D. C. Hornigold, *Biochem. J.*, 2016, **473**, 2881–2891.
- 34 Y.-L. Liang, M. Khoshouei, A. Glukhova, S. G. B. Furness, P. Zhao, L. Clydesdale, C. Koole, T. T. Truong, D. M. Thal, S. Lei, M. Radjainia, R. Danev, W. Baumeister, M.-W. Wang, L. J. Miller, A. Christopoulos, P. M. Sexton and D. Wootten, *Nature*, 2018, **555**, 121–125.

